Psilocybin is under clinical development by Compass Pathways and currently in Phase III for Treatment Resistant Depression. According to GlobalData, Phase III drugs for Treatment Resistant Depression have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin overview
Psilocybin is under development for the treatment of treatment-resistant depressive disorder (P-TRD), autism, anorexia nervosa, obsessive-compulsive disorder (OCD) and body dysmorphic disorder. It is formulated as the capsule and administered by oral route. The drug candidate is a tryptamine alkaloid which is a psychedelic prodrug compound acts by targeting 5hydroxy tryptamine 1A and 2A.
See Also:
The drug candidate was under development for the treatment of major deprresive disorder (MDD).
Compass Pathways overview
Compass Pathways (Compass) is a mental health care company. It focuses on developing psilocybin therapies for treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa. The company is investigating a novel therapy based on its proprietary formulation of synthetic psilocybin, COMP360 in phase IIb clinical studies. The company operates offices in New York, the US. Compass is headquartered in Altrincham, Cheshire, the United Kingdom.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
